LEADER 03106nam  2200733 a 450 
001 9910954143803321
005 20251017110107.0
010   $a9786612083556
010   $a9780309178167
010   $a0309178169
010   $a9781282083554
010   $a1282083554
010   $a9780309120890
010   $a0309120896
035   $a(CKB)1000000000785689
035   $a(OCoLC)726823396
035   $a(CaPaEBR)ebrary10286191
035   $a(SSID)ssj0000114554
035   $a(PQKBManifestationID)11129889
035   $a(PQKBTitleCode)TC0000114554
035   $a(PQKBWorkID)10125386
035   $a(PQKB)11547321
035   $a(MiAaPQ)EBC3378464
035   $a(Au-PeEL)EBL3378464
035   $a(CaPaEBR)ebr10286191
035   $a(CaONFJC)MIL208355
035   $a(OCoLC)923280041
035   $a(Perlego)4736768
035   $a(DNLM)1507722
035   $a(EXLCZ)991000000000785689
100   $a20090925d2009      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aBreakthrough business models $edrug development for rare and neglected diseases and individualized therapies : workshop summary /$fTheresa Wizemann, Sally Robinson, and Robert Giffin ; Forum on Health Sciences Policy, Institute of Medicine of the National Academies
205   $a1st ed.
210   $aWashington, D.C. $cNational Academies Press$d2009
215   $a1 online resource (149 p.)
300   $aBibliographic Level Mode of Issuance: Monograph
311 08$a9780309120883 
311 08$a0309120888 
320   $aIncludes bibliographical references (p. 104-105).
327   $aIntroduction and overview -- Current model for financing drug development : from concept through approval -- The Food and Drug Administration's Orphan Drug Program -- Diverse funding models -- Strategies for facilitating sharing of research materials and data -- Strategies of navigation intellectual property -- Strategies for facilitating clinical trials -- Summary.
330   $a"The Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop on June 23, 2008, titled "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies." The purpose of the workshop was to explore innovative strategies for orphan drug development."--P. 3.
606   $aOrphan drugs$xGovernment policy$zUnited States
606   $aPharmaceutical policy$zUnited States
606   $aDrugs$xDesign$zUnited States
615  0$aOrphan drugs$xGovernment policy
615  0$aPharmaceutical policy
615  0$aDrugs$xDesign
676   $a615/.19
701   $aWizemann$b Theresa M$0890630
701   $aRobinson$b Sally$0620917
701   $aGiffin$b Robert B$01806072
712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910954143803321
996   $aBreakthrough business models$94365673
997   $aUNINA